W9L-16634-21166
3 vaccinations
1 coded response
19 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 292 / SC
- Registered
- 2021-09-01
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-08-16
Dose 1 — Pfizer-BioNTech
-
2021-09-01
Registered in v-safe
- 2021-09-01
-
2021-09-07
Dose 2 — Pfizer-BioNTech
- 2021-09-09
- 2021-09-11
- 2021-09-12
- 2021-09-13
- 2021-09-14
- 2021-09-22
- 2021-09-28
- 2021-10-05
- 2021-10-12
- 2021-10-19
- 2021-12-07
-
2022-04-21
Dose 3 — Pfizer-BioNTech
- 2022-05-04
- 2022-05-07
- 2022-05-12
- 2022-05-21
- 2022-05-26
- 2022-06-05
-
2022-07-21
Survey response — 3 months, dose 3MedDRA: Nasopharyngitis — Feeling: GoodFree text: Common cold symptomsMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-08-16 | Pfizer-BioNTech | No |
| 2 | 2021-09-07 | Pfizer-BioNTech | No |
| 3 | 2022-04-21 | Pfizer-BioNTech | No |
Free text
Release 12 — 3 months, dose 3
Symptoms: Common cold symptoms
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release